AFP and hepatocellular carcinoma: For patients with AFP ≥ 400 ng/mL, ramucirumab (REACH-2) improved OS (HR ~ 0.71) and is FDA-approved; it is the first biomarker-selected therapy validated in phase III HCC [56].